Pain Therapeutics Announces Positive Phase I Study Results With PTI-202

[Guest guest]

Pain Therapeutics Announces Positive Phase I Study Results With PTI-

202

http://www.medicalnewstoday.com/medicalnews.php?newsid=57779

Pain Therapeutics, Inc. (Nasdaq: PTIE) announced positive results

today from a Phase I clinical trial evaluating PTI-202, the

Company's second abuse- resistant opioid painkiller.

This clinical trial was designed to investigate the safety,

tolerability, pharmacokinetics and pharmacodynamic profile of a

single, oral dose of PTI-202 in healthy volunteers. We believe

results also indicate PTI-202 is safe and well-tolerated and its

release profile appears well-suited to use with a chronic pain

population. There were no unexpected adverse events in this trial.

" We are very pleased with the results of this clinical trial, " said

Remi Barbier, president and chief executive officer. " These results

in healthy volunteers nicely recapitulate what we previously

observed in animal studies and provide further evidence that the

underlying abuse-resistant platform can be applied across different

opioid painkillers. "

PTI-202 is a novel abuse-resistant formulation of an opioid

painkiller. Its active pharmaceutical ingredient remains

undisclosed. PTI-202 is intended to meet the needs of physicians who

appropriately prescribe opioid painkillers and who seek to minimize

the risks of drug diversion, abuse or accidental patient misuse.